1 – 2 of 2
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
- 2007
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article